Pulmonary vascular disease & thromboembolismMeta-analysis
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
- Systematic review and network meta-analysis of randomised trials
- additive component network meta-analysis
Authors' conclusion
The present meta-analysis of RCTs suggests that LLT may have a potential for VTE prevention, particularly in high-intensity dosing and in combination therapy.
Study context
- Population
- Randomized controlled trials (RCTs) of statins, ezetimibe or PCSK9 inhibitors; primary venous thromboembolism (VTE) prevention
- Participants
- 254,933 participants · 45 RCTs
- Comparison
- Lipid-lowering therapies vs placebo
- Outcome
- VTE risk
- Follow-up
- Long-term
Pooled result
As reported in the abstract
VTE
Relative risk (95% CI)
PCSK9i + high-intensity statin vs Placebo
0.59(0.43–0.80)
High-intensity statin vs Placebotrend towards reduction
0.84(0.70–1.02)
Low-/moderate-intensity statin vs Placebotrend towards reduction
0.89(0.79–1.00)
Ezetimibe vs Placebodid not affect VTE risk
1.04(0.83–1.30)
PCSK9i + high-intensity statin vs Low-/moderate-intensity statin
0.66(0.49–0.89)
Original publication
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis. Eur Heart J. Published 14 June 2024. doi:10.1093/eurheartj/ehae361
Summarised from the published abstract; every number is checked against it